Carmustine (BCNU): Nitrosourea Alkylating Agent
Carmustine (BCNU) is a chloroethylnitrosourea that alkylates and crosslinks DNA, interfering with DNA replication and RNA transcription. Like lomustine, it is highly lipophilic and readily crosses the blood-brain barrier, achieving therapeutic concentrations in cerebrospinal fluid. Carmustine also inhibits several key enzymatic processes through carbamoylation of amino acids in proteins.
Product Profile
| CAS Number | 154-93-8 |
|---|---|
| Molecular Formula | C5H9Cl2N3O2 |
| Appearance | Light yellow powder or lyophilized solid |
| Therapeutic Category | Antineoplastic / Alkylating Agent |
| Storage | Store at 2–8°C, protect from light |
Applications
Carmustine is administered intravenously for brain tumors (glioblastoma, brainstem glioma, medulloblastoma, astrocytoma), multiple myeloma, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma. It is also available as biodegradable wafer implants (Gliadel) placed directly into the surgical cavity after tumor resection to provide sustained local chemotherapy for recurrent glioblastoma. In conditioning regimens for autologous stem cell transplantation, carmustine is a component of the BEAM protocol (BCNU, etoposide, cytarabine, melphalan). The compound is unstable in solution and must be used within a short time after reconstitution.
Why Source from TCS
TCS supplies carmustine to pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Carmustine 154-93-8?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Carmustine 154-93-8 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Carmustine 154-93-8?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.